|| List of recent Casein-related patents
| Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs|
This invention is related to a pharmaceutical combination that contains a casein kinase 2 (ck2) peptide inhibitor (termed p15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin c, imatinib, iressa, velcade (bortezomib), cytarabine (ara c), fludarabine and mitroxantrone.
Centro De Ingenieria Genetica Y Biotecnologia
|Bioactive complex compositions and methods of use thereof|
A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides.
Texas A&m University System
|Methods for treating heat stress and related compositions|
Methods of treating, reducing, and/or preventing heat stress are provided. For example, provided is a method of treating or preventing heat stress in a subject comprising selecting a subject in need of heat stress treatment or prevention and administering an effective amount of one or more of astaxanthin and milk casein hydrolysate, or a derivative thereof to the subject.
|Method for inhibiting aggregate formation during protein hydrolysis|
Disclosed is for inhibiting gel formation during, or resulting from, hydrolysis of protein compositions comprising casein.. .
Glanbia Nutritionals (ireland) Plc
|Methods for screening inhibitors of tau phosphorylation by casein kinase i|
Methods of screening for candidate compounds capable of inhibiting activity of fyn in phosphorylating tau protein at y394 or binding to fyn to inhibit interaction with tau protein at y394, including determining whether, and optionally the extent, the candidate compounds have these capabilities under conditions where fyn has these capabilities in the absence of the candidate compound. Methods of screening for substances capable of promoting dephosphorylation of tau protein by a phosphatase at a site of tau protein including contacting a candidate substance, the tau protein and a phosphatase capable of dephosphorylating the tau protein under conditions where the phosphatase is capable of dephosphorylating the site in absence of the candidate substance, where the kinase is fyn; determining whether, and optionally the extent, the candidate substance promotes dephosphorylation of the tau protein at the site; and selecting the candidate substance which promotes dephosphorylation of the tau protein the sites..
King's College London
The invention relates to peptides including dede(ssd)ndeg indicated by seq no. 1, rrrdede(ssd)ndeg indicated by seq no.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
|Energy-rich liquid nutritional composition having improved organoleptic properties|
The object of the present invention is to provide a liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, comprising a high protein content, in particular micellar casein as major protein source, in a small volume of liquid, in particular 6 to 20 g protein per 100 ml of the liquid composition, the composition further comprising lactic acid and having a ph in the range of 6 to 8. It is also an object of the invention to provide an improved manufacturing process for such liquid enteral compositions..
|Kluyveromyces lactis yeast strain and methods for the production of sugars, ethanol, beta-galactosidase and biomass|
The present invention is a kluyveromyces lactis yeast strain comprising the sequence identified by seq id no: 1, and methods for the production of sugars (glucose and galactose), ethanol, β-galactosidase and biomass, in which said kluyveromyces lactis yeast strain is cultured in the presence of a lactose-containing medium. The lactose-containing medium may be milk, whey, whey resulting from the preparation of butter, whey resulting after casein precipitation, milk permeate, whey permeate, acid whey and ypl culture medium..
|Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs|
This invention is related to a pharmaceutical combination that contains a casein kinase 2 (ck2) peptide inhibitor (termed p15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin c, imatinib, iressa and velcade (bortezomib).
Centro De Ingenieria Genetica Y Biotecnologia
|Use of fermented milk product for skin treatment|
The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.. .
Quest International Services B.v.
Uses of casein compositions
casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.. .
Fonterra Co-operative Group Limited
Stabilized concentrated liquid human milk fortifier
Disclosed are shelf-stable concentrated liquid human milk fortifiers including extensively hydrolyzed casein. The long term shelf stable, concentrated liquid human milk fortifiers include octenyl succinic acid (osa) modified waxy potato starch as a stabilizer..
Concentrated low water activity liquid human milk fortifier including extensively hydrolyzed protein
Disclosed are concentrated liquid human milk fortifiers including extensively hydrolyzed casein, and optionally a probiotic. The concentrated liquid human milk fortifier has a low water activity and a low ph, thereby reducing microbial growth in the fortifier..
Composition to overcome inhibitors in pcr and growth cultures
Provided herein are compositions and methods for improving amplification or detection of a target nucleic acid in a sample containing pcr inhibitors, such as polyphenols. One aspect provides an enhancer composition including casein or polyvinylpyrrolidone, or a modified polymer thereof.
Method for producing fructosyl valyl histidine oxidase preparation
A method for producing a fvho preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, d-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried fvho preparation, comprising a step of allowing bicine to coexist.. .
Nutritional composition comprising whey and hydrolyzed casein and uses thereof
The present disclosure provides a nutritional composition, such as a preterm infant formula that includes a protein source comprising whey protein and hydrolyzed casein protein. The whey protein to hydrolyzed casein ratio may be from about 90:10 to about 50:50 by weight.
Protein fortified yogurts and methods of making
Methods of making protein-fortified yogurt products are described. The methods may include mixing a casein-containing ingredient with starting milk to make a yogurt milk, where the casein-containing ingredient has a casein-to-whey protein ratio of 82:18 or greater.
Reduced calorie infant formulas containing specific whey to casein ratios
The present disclosure is directed to nutrition systems including at least a first and a second reduced calorie infant formula having varying whey to casein protein weight ratios for reducing inflammation-related diseases later in life. Particularly, the nutrition systems may be administered to a newborn infant to reduce the risk of obesity later in life..
Dietary product intended to reduce visceral fat during the pre-operative phase prior to bariatric surgery
An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.. .
Protein seasonings and methods of making the same
A protein seasoning and methods of making the same are provided. A formulation can be provided comprising a base combined with a protein source, which can be combined with various flavored seasonings/ingredients to form protein seasonings that can be added to different foods and/or liquids.
Method for producing a milk product
A method is disclosed for producing an infant formula base, wherein by means of microfiltration, ultrafiltration, and nanofiltration the components of milk are separated into a casein fraction, a whey protein fraction, and a lactose fraction to produce, by suitably combining, a composition in which the amino acid composition is close to that of human milk. An infant formula base having a total protein concentration of about 1.0 to about 1.5% and a β-casein concentration of at least about 11% of the total protein concentration is also disclosed.
Dietary product intended for the prevention of cardiometabolic risk
A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.. .
Methods for the bioremediation of petroleum in an aquatic environment
In one embodiment, a bioremediation agent and method of bioremediation of an oil spill are disclosed. The bioremediation agent contains oil-digesting bacteria and bacterial nutrients in a buoyant water semi-insoluble and biodegradable casein product.
Reducing the risk of autoimmune disease
The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes.
Crumble process cheese products and methods of production
Crumble process cheese products may be produced by cooling process cheese to freezing temperatures below about 32° f. And holding the process cheese at the freezing temperatures for a sufficient amount of time to cause a freeze-induced denaturation of the protein bonds in the process cheese, thereby providing a modified process cheese with a texture adapted to crumble.
Activating adiponectin by casein hydrolysate
The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight.
Reducing proinflammatory response
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes.
The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest.
Continuous cheese production process
Processes and equipment for continuously making a substitute or imitation cheese by feeding a heated first liquid stream including emulsifying salt, water and cheese powder into a cooker which is a twin screw mixer, feeding a heated second liquid stream including oil and casein or a non-dairy protein into the cooker, processing the first liquid stream and the second liquid stream through the cooker to form a cheese composition, and cooling the cheese composition. The cheese composition may be continuously extruded in a desired shape such as sheets or ropes and/or may be continuously cooled and cut into pieces having a reduced size such as a size to approximate shredded cheese..
Dairy based compositions with low lps
The present invention is directed to a method to produce a dairy based food composition with low lps comprising the steps (a) providing a milk with a storage time of less than 264 hours and either (b1) treating the milk with a microfilter of poresize of from 0.01-2 μm such that at least a casein rich fraction and a serum protein rich fraction is obtained, or (b2) treating the milk such that at least 98 wt % of the gram negative bacteria is removed, and heating the milk wherein at least 98wt % of the gram negative bacteria is removed to 60-90° c. The methods of the present invention are very suitable to provide a dairy based food composition wherein less than 5100 eu lps per liter ready to use food composition is present or wherein less than 39 eu lps per gram dry product is present..
Sterilized liquid protein supplement
Disclosed are sterilized liquid protein supplements including extensively hydrolyzed casein for use with human milk and other infant feeding formulas. The sterilized liquid protein supplements have a low ph, thereby inhibiting protein denaturation and reducing microbial growth..
Exogenous opioid peptide-degrading enzyme
The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from penicillium citrinum, aspergillus oryzae, and aspergilius melleus, and exhibits a degradation activity for a wheat gluten-derived opioid peptide and a casein-derived opioid peptide..
A casein hydrolysate formed by controlled hydrolysis of a casein substrate by an aspergillus-derived (fugal) proteolytic preparation is described. The controlled hydrolysis employs a flavorpro-whey™ formulation and a degree of hydrolysis (% dh) of from 5% dh to 15% dh.
Composition containing s-adenosyl-l-methionine with excellent storage stability
The present invention relates to a composition including s-adenosyl-l-methionine; and at least one kind of additive selected from carboxymethylcellulose, hydroxypropylcellulose, soybean polysaccharide, casein sodium, and zein, in which s-adenosyl-l-methionine is extracted from s-adenosyl-l-methionine-containing cells obtained by culturing a microorganism having an ability to produce same, and the content of the additive in the composition falls within the range of 0.05 to 15 times by mass of s-adenosyl-l-methionine in the composition. The present invention provides a composition containing a high concentration of s-adenosyl-l-methionine, which is useful as a water-soluble physiologically active substance, and being excellent in storage stability and bioabsorbability.
Methods for the remediation of algal blooms
In one embodiment, a remediation agent and method of remediation of an algae bloom are disclosed. The remediation agent contains light absorbing compounds in a buoyant water semi-insoluble and biodegradable casein product.
Composition with improved digestibility of proteins
The present invention relates to method to produce a dairy based food composition comprising protein comprising the steps (a) treating the milk such that at least 98% of the pathogens is removed, (b) treating the milk with a microfilter of a poresize of 0.01-2 micron such that at least a casein rich fraction and a serum protein rich fraction is obtained, wherein the milk is subjected to a heating treatment before or after the microfiltration and wherein during the production the milk and products obtained from the milk are not subjected to a heat treatment at a temperature above 90° c., and wherein the serum protein rich fraction and/or the casein rich fraction is processed into a food product. The invention also is directed to products made by the process..
Compositions and methods for augmenting kidney function
A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise lactobacillus, bacillus, streptococcus bifidobacteria, saccharomyces or leuconostoc.
Enteric delivery of functional ingredients suitable for hot comestible applications
A microencapsulated enteric matrix composition and method for manufacture are provided. The microencapsulated enteric composition includes enteric material, such as sodium caseinate and soy protein, and a functional ingredient contained therein in a core.
Method of producing a composition containing caseino-macropeptide
The present invention pertains to a method of producing caseinomacropeptide (cmp)-containing compositions in high yield and having a very low content of phenylalanine (phe). More specifically, the method involves subjecting a whey derived feed to a combination of ultrafiltration and subsequent cation exchange..
Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition
The invention relates to the use of one or more nucleotides for improving the heat stability of an aqueous micellar casein composition comprising 6 to 20 g per 100 ml of micellar casein, and having a ph of about 6 to 8. The invention also relates to heat-treated liquid nutritional compositions comprising 6 to 20 g, preferably 9-20 g, of protein per 100 ml of the composition and having a ph of about 6 to 8, in which all or a major part of said protein comprises micellar casein, further comprising one or more nucleotides..
Composites containing polypeptides attached to polysaccharides and molecules
This document provides methods and materials related to composites or coatings containing polypeptides attached to polysaccharides and/or molecules. For example, methods and materials related to composites or coatings containing polypeptides (e.g., casein polypeptides) attached to polysaccharides (e.g., cellulose) and/or molecules (e.g., calcium containing molecules such as calcium phosphate and calcium carbonate and/or polyesters such as polylactic acid and polyhydroxybutyrate) are provided.
Aminopyrimidine kinase inhibitors
Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., ck1γ), casein kinase 2 (ck2), pim1, pim2, pim3, the tgfβ pathway, the wnt pathway, the jak/stat pathway, and/or the mtor pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., ck1γ), casein kinase 2 (ck2), pim1, pim2, pim3, the tgfβ pathway, the wnt pathway, the jak/stat pathway, and/or the mtor pathway..
Reduced sodium food products formed of potassium-containing emulsifying salt mixtures and methods of making and using same
A method of preparing a less sodium food product involves forming a reaction mixture of one or more of liquid sodium potassium hydrogen phosphate and liquid sodium dipotassium phosphate and combining a food ingredient with the emulsifying salt mixture. A reduced sodium process cheese product is formed of a sol to gel conversion fat stabilized via a hydrated protein matrix by a combination of potassium caseinate and sodium caseinate in which the caseinates are derived from an emulsifying salt mixture of liquid sodium potassium hydrogen phosphate and liquid sodium dipotassium phosphate, which, prior to reaction, accounts for at least about 2.5 and up to about 8.32 percent by weight of a total weight of the process cheese product.
Method of making a milk protein composition
Described is a method of of providing milk proteins from raw animal milk. The method comprises subjecting the milk to two microfiltration steps.
Method for isolating osteopontin using feeds containing cmp or casein species
The present invention pertains to a method for isolating osteopontin from a milk-derived feed containing caseino macropeptide and/or free beta casein, such as e.g. A feed based on milk serum or sweet whey.
Compositions and methods for improving curd yield of coagulated milk products
Disclosed are compositions and methods for enhancing the yield of coagulated milk products including cheese and other fermented milk products. Admixture of structurally expanded celluloses into milk allows substantial incorporation of additional whey solids and fluids into the caseinate matrix.
Age-tailored nutrition system for infants
The invention relates to the use of a protein source comprising whey and casein proteins for providing an age-tailored nutrition system to an infant which system comprises two infant formulas each appropriate to an infant of a different age and each comprising the protein source wherein the whey casein ratio of each formula is chosen in the range from 100:0 to 40:60 and decreases according to the age of the infant and the protein content of each formula is chosen in the range from 1.5 to 3.0g protein/100 kcal and decreases according to the age of the infant.. .
Age-tailored nutrition system for infants
The invention relates to the use of a protein source comprising whey and casein proteins for providing an age-tailored nutrition system to an infant which system comprises two infant formulas each appropriate to an infant of a different age and each comprising the protein source wherein the whey casein ratio of each formula is chosen in the range from 100:0 to 40:60 and decreases according to the age of the infant and the protein content of each formula is chosen in the range from 1.5 to 3.0 g protein/100 kcal and decreases according to the age of the infant.. .
Methods and compositions of camel derived products
The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (gag)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof.
Casein kinase 1delta (ck 1delta) inhibitors and their use in the treatment of neurode-generative diseases such as tauopathies
The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (ck1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as alzheimer's disease.. .
Pre-thickened compact liquid nutritional composition for dysphagia patients
The invention pertains to a liquid enteral nutritional composition with an energy density between 1.0 and 4.0 kcal/ml, a viscosity between 150 and 1800 mpas measured at a shear rate of 50/second at 20° c., comprising digestible carbohydrates and fat, wherein the composition further comprises at least one of (a1)) between 8-20 g protein per 100 ml of the composition, where micellar casein comprises at least 50 wt % of the total protein content of the composition, or (a2) between 16-45 en % protein, where micellar casein comprises at least 50% of the protein caloric content; and (b) anionic fibers capable of sequestering of calcium, and (c) carrageenan between 0.015 and 0.25 g per 100 ml of the composition, and its use for preventing/treating dysphagia, and/or treating/preventing malnourishment or undernourishment associated with dysphagia.. .
High energy liquid enteral nutritional composition
High energy and high protein liquid nutrition enteral compositions are provided that contain micellar casein and caseinate, an optionally a small amount of whey.. .
Casein kinase 1delta (ck 1delta) inhibitors
The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (ck1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as alzheimer's disease.. .
Cheese and preparing the same
The invention relates to a method for producing cheese, comprising the steps of: providing a milk raw material, subjecting the milk raw material to microfiltration and pre-acidification to produce an acidified casein concentrate, where the microfiltration is performed prior to orsimultaneously with the pre-acidification, concentrating the acidified casein concentrate to produce full concentrated pre-cheese, processing the full concentrated pre-cheese to a cheese product. The invention also relates to cheese having a ratio of total content of β-lactoglobulin and α-lactalbumin to glycomacropeptide of at most about 1.35..
Milk-based product and a its preparation
The invention relates to a whey protein product having a ratio of whey protein to casein in the range from about 25:75 to about less than 50:50, a total protein content of at least 20% on dry matter basis, and a protein content of about 2.5 to about 8% by weight, based on the weight of the product. The product has a favourable amino acid composition and is especially suitable for athletes.
Protein beverage and making same
A protein beverage composition and a method of making it relate to a beverage including a protein essentially free of caseinate and derived from an aqueous protein isolate collected from membrane-filtration isolation of the protein and without substantial drying, wherein the protein beverage composition exhibits a ph ranging from about 2.0 to about 4.6. Substantial solubility of the protein is maintained in the beverage composition, and the protein beverage is essentially free of active microbes known to be harmful to human health, both at the time of packaging of the protein beverage and for a time period of at least one year after packaging..
Method for using an enzyme resistant to high pressures
At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.. .
Milk protein concentrates
A method for making a milk protein concentrate can comprise heating a liquid milk composition at near its natural ph to a temperature that causes the whey protein in the milk to bind to the casein in the milk to form protein aggregates. After cooling, the liquid milk composition can be subjected to membrane filtration using a membrane filter having a large pore size.
Multivalent breast cancer vaccine
Compositions and methods for immunization against human breast cancer are disclosed. In one embodiment the multivalent antigenic composition is provided comprising immunogenic polypeptides selected from the group consisting of human α-lactalbumin, αs1 casein, β-casein and κ-casein..
Isolation, cloning, sequencing and functional analysis of ß-casein promoter along with the regions of exon1, intron1 and exon2 using mammary gland derived cell line of buffalo (bubulus bubalis)
The present invention relates to a method of in vitro isolation of buffalo β-caesin promoter (bucsn2) along with the regions exon1, intron1 and exon2 from the genomic dna in vitro (bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo β-caesin promoter along with exon1, intron1 and exon2 is isolated and cloned upstream of the enhanced green flourescence protein (egfp) gene and sequenced.
Coffee whitener, process for producing same, and process for producing beverage
Coffee whiteners prepared by using, as the aqueous phase thereof, a casein-containing milk protein solution that has been deamidated with a protein deamidating enzyme, exhibit excellent storage stability and dispersibility in coffee without the use of synthetic emulsifiers.. .
Methods for making milk-like beverages
The invention provides methods for making a milk-like beverage compositions comprising creating a homogeneous aqueous mixture of (1) one or more caseinates, (2) whey protein, (3) one or more fats, (4) one or more hydrocolloids, and (5) one or more emulsifiers; heating the aqueous mixture to a temperature of from about 118 to about 127° c. And maintaining such temperature for from about 8 to about 14 minutes; and cooling the heated aqueous mixture to a temperature of from about 20 to about 35° c.
"nanoparticles for the encapsulation of compounds, preparation thereof and use of same"
The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, comprising a casein matrix, a basic amino acid and a metal selected from a divalent metal, a trivalent metal and combinations thereof. Said nanoparticles can encapsulate a water soluble or fat soluble biologically active compound.
Method for producing gardenia blue pigment
Provided is a method for producing a gardenia blue pigment resistant to discoloration which may occur in colored sugar-coated food or pharmaceutical products. The method for producing such a gardenia blue pigment comprises performing membrane separation using a membrane (for example, an ultrafiltration membrane) with a molecular weight cut-off of 3000 da or larger for removal of low-molecular compounds from a solution resulting from β-glucosidase treatment of an iridoid glycoside (for example, geniposide etc.) in the presence of a protein hydrolysate (for example, a casein protein hydrolysate), the iridoid glycoside being obtainable by extraction from fruits of gardenia jasminoides (rubiaceae).